Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer.

• Status: Recruiting
• Trial end date: 2027-01-01

Summary

This is an open-label, phase 1, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.

• Phase: Phase 1

Details

• Lead Sponsor: TILT Biotherapeutics Ltd.
• Collaborator: Merck Sharp & Dohme LLC
• Treatments: Doxorubicin; Liposomal doxorubicin; Pembrolizumab